Merck (MRK.US) obtained positive results in the late-stage trial of experimental RSV in infants.
Pharmaceutical company Merck (MRK.US) stated that its experimental treatment aimed at protecting infants from respiratory syncytial virus (RSV) infections showed positive results in mid-to-late-stage trials. The company mentioned plans to discuss the research data with regulatory institutions worldwide, with the goal of providing treatment for infants during the RSV season as early as 2025 to 2026.
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Investors in Merck (NYSE:MRK) Have Seen Respectable Returns of 48% Over the Past Three Years
"Trump Trade" is restarting, what are the differences?
The new change of the "Trump trade" is that US technology stocks are more resilient, energy stocks are weaker, US bond yields are falling instead of rising, and gold is performing stronger. Ping An Securities believes that the current situation is still in a stalemate, and it is uncertain how far the "Trump trade" can go.
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios